$1.61 Billion Forecast for Monoclonal Antibodies In Veterinary Health Market by 2029, Backed by Demand and Innovation
Discover trends, market shifts, and competitive outlooks for the monoclonal antibodies in veterinary health industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Fast Is The Monoclonal Antibodies In Veterinary Health Market Expected to Grow Between 2025 And 2029?
The market of monoclonal antibodies for veterinary health has seen a significant expansion in the recent past. It is projected to escalate from a size of $0.8 billion in 2024 up to $0.92 billion in 2025, marking a remarkable CAGR of 15.2%. Factors such as the rise in the global ownership of pets, the occurrence of long-term illnesses in animals, a surge in pet adoption and heightened health awareness amongst pet proprietors have led to this growth during the historic period.
In the coming years, the market for monoclonal antibodies in veterinary health is predicted to experience swift expansion. It is projected to reach $1.61 billion by 2029 with a compound annual growth rate (CAGR) of 15.0%. The upswing estimated within the forecast period is due to an escalating pet population, heightened pet expenses, an increasing incidence of canine atopic dermatitis, higher demand for advanced veterinary healthcare, and a growing emphasis on animal health. Future trends predicted for this period include progress in biotechnology and research, advancements in genetic engineering, innovative animal treatments, breakthroughs in antibody-based therapies, and technological progress in antibody engineering.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp
What Are the Core Growth Drivers Propelling the Monoclonal Antibodies In Veterinary Health Market Forward?
An increase in instances of animal disease is anticipated to boost the expansion of the monoclonal antibodies in the veterinary health market. Intensified farming practices, resulting in a higher risk of spreading infectious diseases, and climate change, which broadens the habitat of disease-carrying insects like ticks and mosquitoes, lead to a surge in animal diseases. Monoclonal antibodies are optimal for treating these diseases because they focus on specific pathogens or proteins involved in the disease, providing accurate and potent treatments. For example, a report by GOV.UK, a government website in the UK, published in June 2024, shared that the number of animals culled as a result of TB incidents increased by 5% to 21,298 in England, and 17% to 11,197 in Wales, from April 2023 to March 2024. Therefore, the increasing incidences of animal disease are fueling the growth of the veterinary health market’s monoclonal antibodies.
What Segment Types Define the Monoclonal Antibodies In Veterinary Health Market Structure?
The monoclonal antibodies in veterinary health market covered in this report is segmented –
1) By Animal Type: Dogs, Other Animal Types
2) By Application: Dermatology, Pain, Other Applications
3) By End-User: Veterinary Hospitals, Other End-Users
Subsegments:
1) By Dogs: Canine Infectious Diseases, Canine Cancer Treatment, Canine Autoimmune Disorders, Canine Allergies
2) By Other Animal Types: Cats, Horses, Cattle, Swine, Poultry, Aquatic Animals, Small Mammals
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20575&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Monoclonal Antibodies In Veterinary Health Market?
North America was the largest region in the monoclonal antibodies in veterinary health market in 2024. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Monoclonal Antibodies In Veterinary Health Market?
Leading firms in the market for monoclonal antibodies in veterinary health are concentrating on the development of revolutionary veterinary therapeutics, such as anti-NGF monoclonal antibody treatment for issues like chronic animal discomfort and swelling. This treatment strategy aims at targeting and blocking nerve growth factor (NGF) to alleviate pain and inflammation in animals who suffer from chronic pain conditions. For example, in May 2023, Zoetis, an American animal health organization, earned FDA approval for Librela (bedinvetmab injection), the inaugural monoclonal antibody therapy designed to manage osteoarthritis (OA) related pain in dogs, through a once a month injection, and for Apoquel Chewable, which is the first chewable medicine designed for the treatment of allergic itch and inflammation for dogs aged one year or older. Librela is an antibody that targets and inhibits nerve growth factor (NGF). By intercepting NGF, Librela can interrupt pain signals before they reach the brain, hence reducing the feeling of pain in dogs with osteoarthritis. This novel therapy represents a substantial development in the field of veterinary pain management for dogs suffering from chronic pain.
View the full report here:
What Is the Definition of the Monoclonal Antibodies In Veterinary Health Market?
Monoclonal antibodies in veterinary health are specialized proteins engineered to target and neutralize specific pathogens or toxins in animals, aiding in the diagnosis and treatment of various diseases. They are created by cloning a single type of immune cell to produce identical antibodies that precisely bind to their target.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20575
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
